New mRNA flu shots enter human testing – could they beat the old ones?

NCT ID NCT07204964

Ongoing Prevention Sponsor: GlaxoSmithKline Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests several new mRNA-based flu vaccines in about 971 healthy adults aged 18 and older. The goal is to see how well they trigger an immune response and how safe they are compared to standard flu shots. Participants receive one dose of an experimental vaccine or a comparator, and researchers monitor side effects and antibody levels over time.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: mRNA-based seasonal influenza vaccine candidates (Flu mRNA Formulations A, B1, B3)
What this could lead to: If successful, this could lead to more effective and faster-to-update seasonal flu vaccines for adults.
What could go wrong: This is an early phase 2a study, so the vaccines may not prove more effective than current options. Side effects like injection site pain or fever are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Infections viral infectious disease influenza prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

INFLUENZA, HUMAN

Contacts and locations

Locations

GSK Investigational Site

Guntersville, Alabama, 35976, United States
GSK Investigational Site

Canoga Park, California, 91303, United States
GSK Investigational Site

Walnut Creek, California, 94598, United States
GSK Investigational Site

Hialeah, Florida, 33012, United States
GSK Investigational Site

Miami, Florida, 33186, United States
GSK Investigational Site

Pembroke Pines, Florida, 33025, United States
GSK Investigational Site

Stockbridge, Georgia, 30281, United States
GSK Investigational Site

Carson City, Nevada, 89706, United States
GSK Investigational Site

Las Vegas, Nevada, 89109, United States
GSK Investigational Site

Greensboro, North Carolina, 27408, United States
GSK Investigational Site

North Charleston, South Carolina, 29405, United States
GSK Investigational Site

Austin, Texas, 78705, United States
GSK Investigational Site

Garland, Texas, 75043, United States
GSK Investigational Site

Newport News, Virginia, 23606, United States
GSK Investigational Site

Seattle, Washington, 98104, United States
GSK Investigational Site

Edegem, 2650, Belgium
GSK Investigational Site

Ghent, 9000, Belgium

More trials for these conditions

Other studies related to the condition(s) this trial covers.